X-linked dominant retinitis pigmentosa - Symptoms, Causes, Treatment & Prevention

Overview

Retinitis pigmentosa (RP) is a group of inherited retinal degenerations that lead to progressive loss of photoreceptor cells (rods and cones). While most forms follow an autosomal‑dominant, autosomal‑recessive, or X‑linked recessive inheritance pattern, a rare X‑linked dominant variant has been described in a handful of families worldwide.

Who it affects: Because the gene is located on the X chromosome and the mutation is dominant, both males and females can be affected, but the clinical picture differs:

• Male carriers have only one X chromosome, so the mutant gene is expressed in every cell that carries it, often resulting in a more severe, earlier‑onset disease.
• Female carriers have a second, normal X chromosome. Due to X‑inactivation (lyonization), they may display milder symptoms, but some can develop vision loss comparable to that of affected males.

Prevalence: X‑linked dominant RP is extremely rare—estimated at < 1 in 1 000 000 individuals. For context, RP overall affects about 1 in 4 000 people worldwide (≈ 0.025 %)【1】. The majority of X‑linked RP cases follow a recessive pattern; dominant forms account for < 5 % of all X‑linked RP cases【2】.

Symptoms

Symptoms develop slowly over years and may differ between sexes. The classic “rod‑cone” pattern—initial rod loss followed by cone loss—still applies.

Early (rod‑related) symptoms

• Night blindness (nyctalopia) – difficulty seeing in dim light, often the first sign.
• Reduced peripheral (side‑) vision – “tunnel vision” as rod cells in the retinal periphery degenerate.
• Difficulty adapting to sudden changes in lighting (e.g., stepping from sunlight into a dark room).

Later (cone‑related) symptoms

• Decreased central acuity – blurriness when reading or recognizing faces.
• Color vision deficits – especially difficulty distinguishing blues and greens.
• Glare and light sensitivity (photophobia).
• Visual field constriction progressing to “central island” vision.

Other ocular findings

• Bone‑spicule pigment migration – characteristic clumps of pigment seen on retinal exam.
• Attenuated retinal vessels and optic disc pallor.
• Cystoid macular edema (CME) – swelling of the macula that can cause sudden worsening of central vision.

Systemic associations (rare)

• Some families report hearing loss or vestibular dysfunction, suggesting a syndromic overlap (e.g., Usher‑type features), though this is not typical of the isolated X‑linked dominant form.

Causes and Risk Factors

The disease results from a pathogenic variant in a gene located on the short arm of the X chromosome (Xp22.1‑p22.3). The most frequently implicated gene in X‑linked dominant RP is RPGR (Retinitis Pigmentosa GTPase Regulator), although specific dominant‑acting mutations differ from the more common recessive RPGR alleles.

• Genetic mutation: Missense, nonsense, or splice‑site mutations that create a protein with a dominant‑negative effect, disrupting photoreceptor maintenance.
• Inheritance pattern: An affected mother transmits the mutation to 50 % of her sons (who become affected) and 50 % of her daughters (who become carriers with variable expression).

Risk factors

• Family history of RP, especially X‑linked patterns (male relatives severely affected, affected females with milder disease).
• Carrier status in females—determined by genetic testing.
• No known environmental or lifestyle risk factors have been shown to cause X‑linked dominant RP; it is purely genetic.

Diagnosis

Because symptoms progress slowly, diagnosis often occurs in adolescence or early adulthood, but can be made earlier in families with a known mutation.

Clinical evaluation

• Comprehensive ophthalmic exam – visual acuity, slit‑lamp biomicroscopy, dilated fundus examination.
• Visual field testing (e.g., Goldmann or Humphrey perimeter) – reveals peripheral constriction.
• Electroretinography (ERG) – measures rod and cone function; reduced rod responses are typical early on.
• Optical coherence tomography (OCT) – cross‑sectional imaging of retinal layers; shows thinning of the outer retina and possible CME.
• Fundus autofluorescence (FAF) – highlights metabolic stress in retinal pigment epithelium.

Genetic testing

Next‑generation sequencing panels for inherited retinal dystrophies, or whole‑exome sequencing, can identify pathogenic RPGR variants. Genetic confirmation is essential for:

• Precise counseling about inheritance.
• Eligibility for emerging gene‑specific therapies (e.g., RPGR‑targeted gene therapy trials).
• Distinguishing dominant from recessive X‑linked forms.

Differential diagnosis

Other causes of night blindness and peripheral vision loss must be considered, such as:

• Usher syndrome (combined RP and hearing loss).
• Leber congenital amaurosis.
• Acquired retinal degenerations (e.g., vitamin A deficiency, toxoplasmosis).

Treatment Options

To date, no cure exists for RP, but several interventions can slow progression, improve visual function, and address complications.

Eye‑focused therapies

• Vitamin A supplementation – 15,000 IU/day has been shown in a long‑term study to modestly slow ERG decline, but must be used cautiously and avoided in patients with liver disease or pregnancy【3】.
• Omega‑3 fatty acids (fish oil) – observational data suggest a protective effect; 1 g EPA/DHA daily is commonly recommended.
• Corticosteroid or carbonic anhydrase inhibitor eye drops – first‑line for cystoid macular edema; can improve central vision in 30‑40 % of cases.
• Low‑vision aids – high‑contrast lenses, electronic magnifiers, and mobility training.
• Retinal prostheses (e.g., Argus II) – considered for end‑stage RP with only light perception; FDA‑approved for RP but not yet widely available for X‑linked dominant forms.

Emerging gene‑specific therapies

Clinical trials are evaluating AAV‑mediated RPGR gene replacement. Early‑phase data show safety and potential visual field preservation in a subset of participants. Patients should discuss trial eligibility with a retinal specialist or a center participating in the ClinicalTrials.gov registry.

Systemic and supportive care

• Regular ophthalmology follow‑up (every 6–12 months).
• Genetic counseling for affected individuals and family members.
• Psychosocial support – connecting with patient advocacy groups such as the Retinitis Pigmentosa Foundation.

Living with X‑Linked Dominant Retinitis Pigmentosa

Adapting daily life can preserve independence and quality of life.

Vision‑enhancement strategies

• Lighting: Use bright, glare‑free illumination; position lamps to reduce shadows.
• Contrast: Choose high‑contrast colors for clothing, signage, and home décor.
• Assistive technology: Smartphone apps for magnification, screen‑reading, and navigation (e.g., Seeing AI, Be My Eyes).
• Mobility training: Orientation & mobility (O&M) specialists can teach cane techniques and safe travel strategies.

Occupational considerations

• Advocate for workplace accommodations—adjusted lighting, screen‑reading software, larger print materials.
• Driving assessments: many regions require formal vision testing; if vision falls below legal limits, obtain a restricted or non‑driving license.

Health maintenance

• Maintain a balanced diet rich in antioxidants (leafy greens, berries) and omega‑3 fatty acids.
• Exercise regularly to improve overall circulation, which may benefit retinal health.
• Avoid smoking, which exacerbates oxidative stress in retinal tissue.

Emotional well‑being

Progressive vision loss can cause anxiety and depression. Strategies include:

• Joining support groups (online forums, local meet‑ups).
• Counseling or therapy with a mental‑health professional familiar with visual impairment.
• Mindfulness and stress‑reduction techniques.

Prevention

Because the condition is genetic, primary prevention (preventing the disease from occurring) is not possible. However, secondary prevention—reducing the speed of progression—can be pursued:

• Early genetic diagnosis and counseling to inform family planning.
• Adherence to vitamin A (if prescribed) and omega‑3 supplementation.
• Prompt treatment of treatable complications such as CME.
• Avoidance of excessive sunlight exposure without proper UV protection (wear UV‑blocking sunglasses).

Complications

If left unmanaged, RP can lead to several vision‑related complications:

• Severe visual field loss – may progress to “tunnel vision” and, eventually, only a central island of vision.
• Cystoid macular edema – can cause sudden central vision decline.
• Secondary cataract formation – common in RP patients, often requiring surgical extraction.
• Glaucoma – increased intra‑ocular pressure has been reported in some RP cohorts.
• Legal blindness – definition varies, but typically visual acuity < 20/200 or visual field ≤ 20°.

When to Seek Emergency Care

---

References:
1. Mayo Clinic. “Retinitis pigmentosa.” Accessed March 2024. https://www.mayoclinic.org.
2. NIH Genetics Home Reference. “X‑linked retinitis pigmentosa.” Accessed February 2024.
3. Berson EL, et al. “A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa.” *Arch Ophthalmol*. 1993;111(6):761‑772.
4. ClinicalTrials.gov. “AAV‑RPGR Gene Therapy for X‑linked RP.” Updated 2023. https://clinicaltrials.gov.
5. Cleveland Clinic. “Low Vision Rehabilitation.” Accessed April 2024.
6. World Health Organization. “Blindness and Vision Impairment.” 2022 data.